Contact us: +91 9550333722 040 - 40102781
Structured search
India
Choose your country
Different countries will display different contents
Try our best to find the right business for you.
My chemicalbook

Welcome back!

HomeProduct name listGliclazide

Gliclazide

Synonym(s):N-[[(hexahydrocylopenta[c]pyrrol-2(1H)-yl)amino]carbony]-4-methylbenzene sulfonamide;1-(3-Azabicyclo[3.3.0]oct-3-yl)-3-p-tolylsulphonylurea;Gliclazide

  • CAS NO.:21187-98-4
  • Empirical Formula: C15H21N3O3S
  • Molecular Weight: 323.41
  • MDL number: MFCD00409893
  • EINECS: 244-260-5
  • SAFETY DATA SHEET (SDS)
  • Update Date: 2024-11-04 20:04:50
Gliclazide Structural

What is Gliclazide?

Chemical properties

White Cyrstalline Solid

Originator

Diamicron,Servier,France,1972

The Uses of Gliclazide

Gliclazide is an oral hypoglycemic agent used to treat non-insulin-dependent diabetes mellitus.Treatment of diabetes associated with obesity or vascular disease, for adults with type 2 diabetes.Diabetes is a chronic (long-lasting) health condition that affects how your body turns food into energy. Gliclazide reduces blood glucose levels by stimulating insulin secretion from the β-cells of the islets of Langerhans.

Background

Gliclazide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It has been classified differently according to its drug properties in which based on its chemical structure, gliclazide is considered a first-generation sulfonylurea due to the structural presence of a sulfonamide group able to release a proton and the presence of one aromatic group. On the other hand, based on the pharmacological efficacy, gliclazide is considered a second-generation sulfonylurea which presents a higher potency and a shorter half-life. 

Indications

For the treatment of NIDDM in conjunction with diet and exercise.

Definition

ChEBI: Gliclazide is a N-sulfonylurea. It has a role as a hypoglycemic agent, a radical scavenger and an insulin secretagogue.

Manufacturing Process

To a suspension containing 4.86 parts of 4-methylbenzenesulfonyl urethane (MP 80° to 82°C) and 36 parts of anhydrous toluene there are rapidly added 2.5 parts of N-amino-3-azabicyclo(3.3.0)octane (BP/18 mm = 86°C). The reaction mixture is heated under reflux for 1 hour. The resulting clear solution crystallizes on cooling. The crystals are filtered, washed with 2 parts of toluene, then recrystallized from anhydrous ethanol. There are obtained 3.8 parts of the desired product, MP 180° to 182°C.

Therapeutic Function

Oral hypoglycemic

Mechanism of action

Gliclazide belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. 

General Description

Chemically, gliclazide, 1-(3-azabicyclo[3.3.0]oct-3-yl)-3-p-tolylsulphonylurea (Diamicron), isvery similar to tolbutamide, with the exception of the bicyclicheterocyclic ring found in gliclazide. The pyrrolidineincreases its lipophilicity over that of tolbutamide,which increases its half-life. Even so, the p-methyl is susceptibleto the same oxidative metabolic fate as observedfor tolbutamide, namely, it will be metabolized to a carboxylicacid.

Biochem/physiol Actions

Oxidative modification of low-density lipoprotein (LDL) plays an important role in vascular dysfunction associated with diabetes mellitus. Gliclazide is a second-generation sulfonylurea with free-radical-scavenging activity. Incubation of human aortic smooth muscle cell (HASMC) with native human LDL (100 μg/mL) in the presence of increasing concentrations of gliclazide (1 to 10 μg/mL) resulted in a dose-dependent decrease in HASMC-mediated LDL oxidation. Exposure of HASMCs to gliclazide (1 to 10 μg/mL) and native LDL (100 μg/mL) also led to a dose-dependent decrease in oxidized LDL-induced human monocyte adhesion to HASMCs. In addition, incubation of HASMCs with gliclazide dramatically reduced the ability of oxidized LDL to stimulate the proliferation of these cells. Finally, treatment of HASMCs with gliclazide resulted in a marked decrease in oxidatively modified LDL-induced monocyte chemoattractant protein (MCP)-1 and human heat shock protein 70 (HSP 70) expression, both at the gene and protein levels. These results show that gliclazide, at concentrations in the therapeutic range (5 to 10 μg/mL), is effective in vitro in reducing vascular smooth muscle cell (VSMC) dysfunction induced by oxidatively modified LDL. Administration of gliclazide to type 2 diabetic patients could form part of the strategy for the prevention and management of diabetic cardiovascular diseases

Pharmacokinetics

Based on the pharmacological properties, gliclazide is a second generation sulphonylurea which acts as a hypoglycemic agent. It stimulates β cells of the islet of Langerhans in the pancreas to release insulin. It also enhances peripheral insulin sensitivity. Overall, it potentiates insulin release and improves insulin dynamics.

Toxicity

LD50=3000 mg/kg (orally in mice). Gliclazide and its metabolites may accumulate in those with severe hepatic and/or renal dysfunction. Symptoms of hypoglycemia include: dizziness, lack of energy, drowsiness, headache and sweating.

Drug interactions

Potentially hazardous interactions with other drugs
Analgesics: effects enhanced by NSAIDs.
Antibacterials: effects enhanced by chloramphenicol, sulphonamides, tetracyclines and trimethoprim; effect reduced by rifamycins.
Anticoagulants: effect possibly enhanced by coumarins; also possibly changes to INR.
Antifungals: concentration increased by fluconazole and miconazole and possibly voriconazole - avoid with miconazole.
Lipid-regulating drugs: possibly additive hypoglycaemic effect with fibrates.
Sulfinpyrazone: enhanced effect of sulphonylureas.
When gliclazide is used with nonsteroidal anti-inflammatory drug (especially salicylates), sulfa antibiotic, double coumarin anticoagulants, monoamine oxidase inhibitors, β-blockers, tetracycline, chloramphenicol, dicyclohexyl B piperidine, clofibrate, ethanol and other drugs, its dosage should be reduced to avoid hypoglycemia reaction.

Absorption

Rapidly and well absorbed but may have wide inter- and intra-individual variability. Peak plasma concentrations occur within 4-6 hours of oral administration.

Metabolism

Extensively metabolized in the liver. Less than 1% of the orally administered dose appears unchanged in the urine. Metabolites include oxidized and hydroxylated derivates, as well as glucuronic acid conjugates.

Metabolism

Gliclazide is extensively metabolised in the liver to metabolites that have no significant hypoglycaemic activity.
Metabolites and a small amount of unchanged drug are excreted in the urine.

Properties of Gliclazide

Melting point: 163-169 °C (lit.)
Density  1.2205 (rough estimate)
refractive index  1.6740 (estimate)
storage temp.  2-8°C
solubility  methylene chloride: soluble
form  powder
pka 6.07±0.10(Predicted)
color  white
Merck  14,4439
InChI InChI=1S/C15H21N3O3S/c1-11-5-7-14(8-6-11)22(20,21)17-15(19)16-18-9-12-3-2-4-13(12)10-18/h5-8,12-13H,2-4,9-10H2,1H3,(H2,16,17,19)
CAS DataBase Reference 21187-98-4(CAS DataBase Reference)
EPA Substance Registry System Benzenesulfonamide, N-[[(hexahydrocyclopenta[c]pyrrol-2(1H)-yl)amino]carbonyl]-4-methyl (21187-98-4)

Safety information for Gliclazide

Signal word Warning
Pictogram(s)
ghs
Exclamation Mark
Irritant
GHS07
GHS Hazard Statements H302:Acute toxicity,oral

Computed Descriptors for Gliclazide

InChIKey BOVGTQGAOIONJV-UHFFFAOYSA-N
SMILES C1(S(NC(NN2CC3CCCC3C2)=O)(=O)=O)=CC=C(C)C=C1

Abamectin manufacturer

SNECOFRi PVT LTD

1Y
Phone:+91-9032850129
Whatsapp: +91 9032850129
product: 21187-98-4 99%
Inquiry

Dikora Bulk Drug Pvt. Ltd.

1Y
Phone:+91-7588687403
Whatsapp: +91 7588687403
product: 21187-98-4 Gliclazide 99%
Inquiry

Reliance Rasayan Pvt Ltd

1Y
Phone:+919427160241
Whatsapp: +91 9427160241
product: Glyclazide 99%
Inquiry

KARPSCHEM LABORATORIES PVT. LTD.

1Y
Phone:+917249203006
Whatsapp: +91 7249203006
product: Gliclazide 1-(Hexahydrocyclopenta[c]pyrrol-2(1H)-yl)-3-[(4- methylphenyl)sulfonyl]urea 21187-98-4 96%
Inquiry

Medi Pharma Drug House

1Y
Phone:+919930911911
Whatsapp: +91 9930911911
product: Gliclazide 99%
Inquiry

Horizon

1Y
Phone:+917517039862
Whatsapp: +91 7517039862
product: Gliclazide 99%
Inquiry

Bajaj Healthcare Ltd

1Y
Phone:+91-2266177400
product: Gliclazide 21187-98-4 98%
Inquiry

Organo Chem (India)

1Y
Phone:+91-9810846377
Whatsapp: +91 9810846377
product: 21187-98-4 Gliclazide 98%
Inquiry

Integrin Life Sciences. Pvt. Ltd.

1Y
Phone:+91-9849990870
Whatsapp: +91-9849990870
product: 21187-98-4 99%
Inquiry

Related products of tetrahydrofuran

You may like

Statement: All products displayed on this website are only used for non medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.